informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia Purpose To describe current treatment patterns in the real-world setting among CLL patients who are beginning treatment with approved oral kinase inhibitors or other approved anti-CLL therapies/regimens as well as any association with patient characteristics, healthcare resource utilization, clinical outcomes, & patient-reported outcomes. Criteria At least 18 years of age Clinical diagnosis of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL) Beginning treatment within +/- 30 days of enrollment Willing & able to provide written informed consent Willing & able to complete patient reported outcome questionnaires Willing & able to provide information on patient survey questionnaires Willing to provide a blood sample at time of enrollment You Cannot: Be diagnosed with any B-Cell malignancy other than CLL/SLL Have a life expectancy of less than 6 months Details Relevant data will be retrieved from the patient medical record & recorded into the registry electronic case report forms along with the completion of the patient reported outcome quesationniare : Baseline Every 3 months for the 1st 6 months Every 6 months thereafter for a minimum of 2 years Interested in more information on this clinical research study? Contact WK Cancer Center Clinical Research Department at 318-212-8671 Interested in more information? Contact Us: Hematology Oncology Associates IRB: Advarra Institutional Review Board IRB Number: Trial Type: NA Sponsor: Pharmacyclics LLC